IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...
Galea, H. , Perry, M. and Jones, P. (2026) Characterising Irritable Bowel Syndrome: An Exploratory Cross-Sectional Study .
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...
Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable ...
In this study, 3,319 unselected, pan-cancer Jordanian patients diagnosed between April 2021 and September 2022 received GGT. Pathogenic germline variant (PGV) frequency among patients who were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback